Trials / Completed
CompletedNCT00667082
NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- Celgene · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a clinical trial examining the safety, pharmacokinetics, pharmacodynamics and efficacy of IV NPI-0052 (a proteasome inhibitor) in combination with oral vorinostat (Zolinza; a HDAC inhibitor) in patients with non-small cell lung cancer, pancreatic cancer, melanoma or lymphoma. Proteasome inhibitors block the breakdown of proteins by cells and HDAC inhibitors block modification of proteins regulating gene expression in cells. Both of these actions preferentially affect cancer cells, and the combination of the two has been seen to have a greater effect in laboratory studies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NPI-0052 (marizomib) + vorinostat | NPI-0052 IV injection over 1 to 10 minutes at doses ranging from 0.15 to 0.7 mg/m2 on Days 1, 8, and 15 of each 28-day Cycle Oral vorinostat 300 mg was administered with food on Days 1 to 16 of each 28-day Cycle |
Timeline
- Start date
- 2008-03-01
- Primary completion
- 2010-01-01
- Completion
- 2010-01-01
- First posted
- 2008-04-25
- Last updated
- 2017-11-22
Locations
3 sites across 1 country: Australia
Source: ClinicalTrials.gov record NCT00667082. Inclusion in this directory is not an endorsement.